HTG Appoints William Radany CEO
Complete the form below to unlock access to ALL audio articles.
HTG, Inc. has announced the appointment of Dr. William Radany to the position of chief executive officer.
He replaces Kirk Collamer who will remain with the company as the chief financial officer.
Dr. Radany joins HTG from Chemicon International where he was vice president of business segment management.
"Bill Radany is a proven industry leader who brings more than 20 years of experience in the pharmaceutical and drug discovery technologies industries to HTG," said Bruce Seligmann, chairman, HTG.
"His strong leadership and management skills will be instrumental in guiding the company's pursuit of both short and long-term growth objectives."
"I am excited to work closely with the Board of Directors and the management team at HTG to continue to bring the Company's gene expression profiling technology to the forefront of drug discovery research. HTG's technology platform brings tremendous value to lab researchers," said Dr. Radany.
"With my experience at life sciences and biotech companies alike, I'm looking forward to applying my experience and insight at HTG to take the business to the next level and expand the Company's customer base which currently includes leading pharmaceutical companies such as Merck & Co., Sanofi Aventis, Bristol Meyers Squibb, Celgene and Takeda, Inc."
Prior to Chemicon International, Dr. Radany was chief business officer at Xencor where he headed up corporate strategy for partnering of Xencor proteomics technologies.
He has also served as vice president of drug discovery programs at both Caliper Technologies Corp. and Strategene respectively.
Prior to Strategene, Dr. Radany was president of Biacore, a proteomics technology company and previously founded the in vitro diagnostic cell culture company NeoGenex and subsequently sold the Company to Diagnostic Hybrids, Inc.
Dr. Radany earned a B.S. in cell biology from Colorado State University and a doctorate in biochemistry/physiology from the University of Wyoming.
HTG's ArrayPlate qNPAT technology is used to carry out quantitative multiplexed, gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development.
HTG's ArrayPlate lysis-only quantitative Nuclease Protection Assay (qNPAT) platform allows scientists to test any sample while avoiding the need for extraction or target amplification.
The platform is designed to provide quantitative test results, including QSAR-quality dose response data and EC50's, enabling clients to compress drug discovery and development program timelines.
